Creative Biolabs is a CRO company dedicated to exploiting the natural activation of T cells and our T cell antigen connector (TAC) platform against both liquid and solid tumors. Headquartered in New York City, it was founded in 2005 by a group of leading cell therapy scientists and researchers. We are working to bring a variety of novel cell therapies to cancer patients to address the limitations of currently available immunotherapies.
In the past few decades, Creative Biolabs is designed to address the multiple challenges caused by TAC-T cells, providing well-mature comprehensive solutions for TAC modification and safety assessment. As a result, solving based on the key issues in the field of TAC - T cell therapy has a unique advantage, most notably through the discovery and development of high efficiency and specificity of TAC gene delivery technologies.
In our company, the production of TAC-T cells has been done through viral vectors, including but not limited to, retroviruses, lentiviruses, herpes simplex viruses, murine Stem Cell Viruses (MSCV), adenoviruses, as well as adeno-associated viruses. The studies conducted by our labs have shown that these vectors can provide low pathogenicity, genetic safety, and efficient transduction for TAC-based virus packaging. Therefore, it has been considered a typical vector type for TAC gene delivery.
| Viral Vectors | Non-Viral Vectors | ||
|---|---|---|---|
| Electroporation | Polymer- and Lipid-based Nanoparticles | ||
| Efficiency | Low-High | High | Low-High |
| Viability | High | Low | High |
| Advantages | Stable and Transient Transfection | High Gene Delivery Volume |
High Flexible Design Suitable for Both In Vivo and In Vitro Studies |
| Limitations |
High Cost Low Production Capacity Low Gene Delivery Volume |
Risk of Cytotoxicity Absence of Cytoplasmic Inclusions Not suitable for Mass Production Suitable for In Vivo Study Only |
High Risk of Toxicity Low Transfection Efficiency |
In recent years, Creative Biolabs democratizes cellular therapy for cancer treatment by adopting a non-viral vector manufacturing process that reduces the cost of treatment while improving the safety of cellular therapy. Creative Biolabs exclusively licenses a strong set of non-viral vector patents for the production of engineered TAC-T cells for oncology.
Fig.1 The Example for One Lentivirus TAC Expression Vector.
Our non-viral vector platform is based on two methods including electroporation and nanoparticles. Electroporation uses impulse voltage and current to create transient tiny holes in the cell membrane, thus achieving transgene expression. For example, we have produced stable engineered CD19 TAC cells by modulating the amplitude, frequency, duration, and number of electrical pulses. Moreover, a wide variety of polymer- and lipid-based nanoparticles, such as PDMAEMA, PEI, PβAE, PEG, and lipofectamine LTX, have been coated with TAC gene to transfer into T cells using a pressurized carrier gas. Our vector platform can be modified to target virtually any cancer antigen using our library of licensed gene-editing protein building blocks.
Fig.2 Strategies for TAC Gene-Delivery by Non-Viral Vectors.
Our TAC virus expression vector is a highly effective vector tool for delivering TAC expression elements into T cells. For example, the lentivirus TAC expression vector was first constructed into a plasmid in Escherichia coli, and the entire TAC expression structure sequence, including the scFv region, TCR-CD3 complex region, and TCR recruitment region, was cloned and then transfected into packaging cells. The specific carrier DNA is further transcribed into RNA, which is then packaged into a virus with the help of certain viral proteins. These live viruses are released into the supernatant, which can be used to infect target cells. During viral infection of T cells, RNA is transported into the cell, where it is retro-scribed into DNA and randomly integrated into the host genome.
Fig.3 qPCR Standard Curve of TAC Lentivirus Titration.
Creative Biolabs is a forward-looking biochemistry company as well as a leading custom service provider in the field of TAC-engineered T-cell therapy services. We can provide many flexible options, from which you can always find a better match for your particular project. Please feel free to contact us for more information.
For Research Use Only
